<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="91259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917006</url>
  </required_header>
  <id_info>
    <org_study_id>191622-133</org_study_id>
    <secondary_id>2013-001650-94</secondary_id>
    <nct_id>NCT01917006</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of BOTOX® in Premature Ejaculation</brief_title>
  <official_title>An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of BOTOX® (onabotulinumtoxinA) for the treatment of
      premature ejaculation in male patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, multicenter, randomized, double-blind, placebo-controlled,
      dose-escalation study to assess a range of doses of BOTOX for the treatment of male patients
      with PE. Patients will attend a minimum of 6 or 7 clinic visits and also have

      1 or 2 telephone visits. Partners will need to attend a clinic visit during the screening
      period to provide informed consent and to receive training on measurement and recording of
      the IELT.

      Patients will be enrolled in cohorts. Within the first 5 cohorts, 8 patients are to receive
      BOTOX and 2 patients to receive placebo. For cohort 6, 12 patients will receive BOTOX and 12
      patients will receive placebo. Patients will receive a single treatment of study medication
      delivered bilaterally to the bulbospongiosus muscle. The initial BOTOX total dose in this
      dose escalation study will be 5 U and the maximum BOTOX total dose will be 100 U. Upon
      request and if eligible, patients in cohort 6, will have the option to receive a second
      injection of BOTOX (open label).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average IELT</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Geometric Mean IELT</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) injected into specified muscle per protocol on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.</description>
    <arm_group_label>OnabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 2</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 3</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 4</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 5</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA Dose 6</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>Botulinum Toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo (normal saline) injected into specified muscle per protocol on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of premature ejaculation

          -  Stable monogamous sexual relationship with female partner for at least 6 months, and
             intends to continue with the same partner for the duration of the study

          -  Patient has ability to follow study instructions and complete study assessment tools

        Exclusion Criteria:

          -  Premature ejaculation caused by medical or surgical issues, or is related to stress
             or other issues (eg, relationship problems)

          -  Pain with ejaculation

          -  Planned use of topical penile treatments (eg, anesthetics, herbal treatments) or
             penile injections during the study

          -  Prior genital, prostatic or lower urinary tract surgery (other than vasectomy or
             circumcision)

          -  Previous or current usage of botulinum toxin therapy of any serotype for any
             urological condition

          -  Use of botulinum toxin therapy of any serotype for any nonurological condition (eg,
             cosmetic, chronic migraine) during the 12 weeks prior to screening, or planned usage
             during the study

          -  Diagnosis of Myasthenia gravis, Eaton‐Lambert Syndrome, Amyotrophic Lateral Sclerosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PE Team</last_name>
    <email>infoUSA@peproblems.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LA Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Center</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Marital and Sexual Health of South Florida</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>Denmark Hill</city>
        <state>London</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>Praed Street</city>
        <state>London</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
